ITI Highlighted as Life Sciences Leader in Montgomery County, MD
Articles Blog PressImmunomic Therapeutics highlighted in Washington Business Journal as a life sciences leader in Maryland’s Montgomery County: The Immunology Capital Next to the Nation’s Capital. Click here to read more: http://ow.ly/NQrc50IVzkTRead moreOncology Tube Interview: ITI-3000 First-In-Human Trial for Merkel Cell Carcinoma
Articles Blog Featured PressClaire Rosean, Senior Scientist discusses ITI-3000, First-In-Human Trial for Merkel Cell Carcinoma and the preclinical data presented at AACR. Click below to watch the full interview: https://www.oncologytube.com/video/40935/claire-rosean-phd-immunomix-uw-aacr22-mcc-iti-3000-first-in-human-trial?channelName=AACRRead moreITI to Participate at World Vaccine Congress Washington 2022
Featured Highlights Press Press ReleasesApril 14, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today thatRead moreITI Reports Preclinical Data on Its MCPγV-LT and Her2/Neu DNA Vaccines at AACR 2022
Featured Highlights Press Press ReleasesBoth DNA Cancer Vaccines Studied Were Derived from Immunomic’s UNITE™ Platform Phase 1 Study of MCPyV-LT Vaccine in Merkel Cell Carcinoma to Begin in Q2 April 08, 2022 01:15 PM EasternRead moreITI Announces Two Poster Presentations at AACR Annual Meeting 2022
Featured Highlights Press Press ReleasesMarch 31, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today thatRead moreExclusive: Rockville biotech expanding, ‘on the prowl’ for talent ahead of planned IPO
Articles PressRead the latest Washington Business Journal article highlighting Immunomic Therapeutics by clicking the link below: https://www.bizjournals.com/washington/news/2022/03/17/immunomic-therapeutics-expanding-hiring-pre-ipo.htmlRead moreITI to present at the BIO CEO & Investor Conference 2022
Featured Highlights Press Press ReleasesFebruary 11, 2022 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced todayRead moreITI Announces Clinical Trial of ITI-3000 for the Treatment of Merkel Cell Carcinoma
Featured Highlights Press Press ReleasesFebruary 07, 2022 01:48 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleicRead more- Featured Highlights Press Press ReleasesNovember 30, 2021 02:01 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced the openingRead more
Immunomic Therapeutics Announces Collaboration With iOncologi
Featured Highlights Press Press Releases- Potential to bring in-house cell-based therapies that potentiate checkpoint inhibitors November 23, 2021 06:41 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”) a privately held clinical-stage biotechnologyRead more- Featured Highlights Press Press ReleasesNovember 18, 2021 ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (‘ITI’), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced that Kristen Batich, MD, Ph.D.Read more
Immunomic Therapeutics Expands Board of Directors with Appointments of Two New Members
Featured Highlights Press Press ReleasesJuly 27, 2021 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced todayRead more